TOP1 and small cell lung carcinoma: Currently, for recurrent or progressive SCLC, the only drug approved in the United States and Europe is topotecan, a topoisomerase 1 (Top1) inhibitor which provides some benefit, though the five year survival rate of SCLC has remained unchanged at~5% for the last four decades [2].